Blue Capital Inc. Takes $707,000 Position in Exelixis, Inc. $EXEL

Blue Capital Inc. acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 16,478 shares of the biotechnology company’s stock, valued at approximately $707,000.

A number of other large investors have also recently bought and sold shares of EXEL. RHS Financial LLC increased its holdings in shares of Exelixis by 2.4% in the 4th quarter. RHS Financial LLC now owns 12,619 shares of the biotechnology company’s stock worth $553,000 after buying an additional 293 shares during the last quarter. Meeder Advisory Services Inc. lifted its stake in shares of Exelixis by 5.8% in the 4th quarter. Meeder Advisory Services Inc. now owns 5,406 shares of the biotechnology company’s stock valued at $237,000 after purchasing an additional 298 shares during the last quarter. Cim LLC lifted its stake in shares of Exelixis by 0.9% in the 3rd quarter. Cim LLC now owns 35,397 shares of the biotechnology company’s stock valued at $1,462,000 after purchasing an additional 305 shares during the last quarter. J.W. Cole Advisors Inc. boosted its holdings in shares of Exelixis by 6.5% in the 4th quarter. J.W. Cole Advisors Inc. now owns 5,354 shares of the biotechnology company’s stock worth $235,000 after purchasing an additional 329 shares during the period. Finally, Fifth Third Wealth Advisors LLC boosted its holdings in shares of Exelixis by 3.8% in the 1st quarter. Fifth Third Wealth Advisors LLC now owns 9,077 shares of the biotechnology company’s stock worth $389,000 after purchasing an additional 333 shares during the period. 85.27% of the stock is currently owned by institutional investors.

Exelixis Stock Performance

Shares of NASDAQ:EXEL opened at $55.85 on Friday. The firm’s 50 day simple moving average is $50.38 and its 200-day simple moving average is $45.90. Exelixis, Inc. has a one year low of $33.76 and a one year high of $56.21. The firm has a market cap of $14.04 billion, a PE ratio of 18.55, a price-to-earnings-growth ratio of 1.56 and a beta of 0.42.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.12. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The firm had revenue of $610.81 million during the quarter, compared to analyst estimates of $607.51 million. During the same quarter in the previous year, the business earned $0.55 earnings per share. Exelixis’s quarterly revenue was up 10.0% on a year-over-year basis. Equities research analysts predict that Exelixis, Inc. will post 3.16 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

EXEL has been the topic of several recent research reports. Zacks Research lowered Exelixis from a “strong-buy” rating to a “hold” rating in a report on Thursday, March 5th. HC Wainwright reaffirmed a “buy” rating and set a $56.00 price objective on shares of Exelixis in a research note on Thursday. Morgan Stanley reiterated a “positive” rating on shares of Exelixis in a research report on Monday, June 22nd. Citizens Jmp raised their target price on shares of Exelixis from $50.00 to $55.00 and gave the stock a “market outperform” rating in a report on Wednesday, June 24th. Finally, Truist Financial cut shares of Exelixis from a “buy” rating to a “hold” rating and lifted their price target for the stock from $51.00 to $54.00 in a research note on Thursday, June 25th. Nine analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $47.60.

Insider Buying and Selling at Exelixis

In other news, EVP Dana Aftab sold 43,451 shares of the firm’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $50.35, for a total transaction of $2,187,757.85. Following the transaction, the executive vice president owned 594,741 shares in the company, valued at approximately $29,945,209.35. This trade represents a 6.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Jack L. Wyszomierski sold 3,925 shares of Exelixis stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $50.55, for a total value of $198,408.75. Following the completion of the sale, the director owned 284,384 shares of the company’s stock, valued at $14,375,611.20. The trade was a 1.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 219,170 shares of company stock worth $10,620,641 over the last quarter. Insiders own 2.60% of the company’s stock.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.